Adverum Biotechnologies Inc (ADVM)
8.01
-0.24
(-2.91%)
USD |
NASDAQ |
May 17, 16:00
8.01
0.00 (0.00%)
After-Hours: 20:00
Adverum Biotechnologies Cash from Operations (Quarterly): -23.24M for March 31, 2024
Cash from Operations (Quarterly) Chart
Historical Cash from Operations (Quarterly) Data
Date | Value |
---|---|
March 31, 2024 | -23.24M |
December 31, 2023 | -21.33M |
September 30, 2023 | -23.91M |
June 30, 2023 | -23.25M |
March 31, 2023 | -22.41M |
December 31, 2022 | -18.48M |
September 30, 2022 | -31.81M |
June 30, 2022 | -28.88M |
March 31, 2022 | -28.93M |
December 31, 2021 | -25.82M |
September 30, 2021 | -25.80M |
June 30, 2021 | -33.92M |
March 31, 2021 | -22.30M |
December 31, 2020 | -22.22M |
September 30, 2020 | -26.54M |
June 30, 2020 | -16.91M |
March 31, 2020 | -13.62M |
December 31, 2019 | -14.84M |
September 30, 2019 | -9.53M |
June 30, 2019 | -11.59M |
March 31, 2019 | -13.22M |
December 31, 2018 | -12.73M |
September 30, 2018 | -16.90M |
Date | Value |
---|---|
June 30, 2018 | -11.35M |
March 31, 2018 | -12.98M |
December 31, 2017 | -12.20M |
September 30, 2017 | -9.985M |
June 30, 2017 | -11.42M |
March 31, 2017 | -11.82M |
December 31, 2016 | -8.342M |
September 30, 2016 | -9.647M |
June 30, 2016 | -8.224M |
March 31, 2016 | -12.15M |
December 31, 2015 | -9.126M |
September 30, 2015 | -9.22M |
June 30, 2015 | -9.25M |
March 31, 2015 | -7.742M |
December 31, 2014 | -5.055M |
September 30, 2014 | -4.973M |
June 30, 2014 | 5.727M |
March 31, 2014 | -1.347M |
December 31, 2013 | -0.721M |
September 30, 2013 | -0.59M |
June 30, 2013 | -0.72M |
March 31, 2013 | -0.144M |
Cash From Operations Definition
Cash flow from operations is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall operating activities of the company. A few examples of operating activities include change in receivables, change in inventories, and changes in current assets.
Cash from Operations (Quarterly) Range, Past 5 Years
-33.92M
Minimum
Jun 2021
-9.53M
Maximum
Sep 2019
-22.27M
Average
-22.83M
Median
Cash from Operations (Quarterly) Benchmarks
Ligand Pharmaceuticals Inc | 18.73M |
Ardelyx Inc | -35.72M |
Arcus Biosciences Inc | -2.00M |
Arcutis Biotherapeutics Inc | -31.60M |
SeaStar Medical Holding Corp | -4.485M |
Cash from Operations (Quarterly) Related Metrics
Cash from Investing (Quarterly) | -22.03M |
Cash from Financing (Quarterly) | 119.88M |
Free Cash Flow | -92.55M |
Free Cash Flow Per Share (Quarterly) | -1.416 |
Free Cash Flow Yield | -98.43% |